MBX Biosciences (MBX) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for MBX Biosciences (MBX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||
Research And Development | 18M | - | 19M (+8.75%) | 18M (-20.93%) | 22M (+47.24%) | 15M (-9.13%) | 17M (+16.32%) | 14M (+30.32%) | 11M (-43.22%) | 19M (+114.55%) | 9.07M | - | - |
Selling General And Administrative | 8.79M | - | 4.66M (+14.22%) | 4.08M (-0.97%) | 4.12M (+21.53%) | 3.39M (+18.12%) | 2.87M (+26.99%) | 2.26M (-0.44%) | 2.27M (-53.77%) | 4.91M (+162.57%) | 1.87M | - | - |
Operating Expenses | 27M | - | 24M (+9.72%) | 22M (-17.79%) | 27M (+42.56%) | 19M (-5.10%) | 20M (+17.71%) | 17M (+25.17%) | 13M (-45.38%) | 24M (+122.56%) | 11M | - | - |
Depreciation And Amortization | 60K | - | 100K (0.00%) | 100K (+25.00%) | 80K | - | 100K (0.00%) | 100K (+100.00%) | 50K (-16.67%) | 60K (-40.00%) | 100K | - | - |
Operating Income | |||||||||||||
Operating Income | -27.26M | - | -23.93M (+9.77%) | -21.80M (-17.83%) | -26.53M (+42.56%) | -18.61M (-5.10%) | -19.61M (+17.71%) | -16.66M (+25.17%) | -13.31M (-45.38%) | -24.37M (+122.76%) | -10.94M | - | - |
Ebit | -27.26M (-68.67%) | -87.00M (+263.56%) | -23.93M (+9.77%) | -21.80M (-17.83%) | -26.53M (+42.56%) | -18.61M (-5.10%) | -19.61M (+17.71%) | -16.66M (+25.17%) | -13.31M (+23.13%) | -10.81M (-1.19%) | -10.94M (+43.76%) | -7.61M (+27.90%) | -5.95M |
EBITDA | -27.20M (-68.74%) | -87.00M (+265.09%) | -23.83M (+9.82%) | -21.70M (-17.96%) | -26.45M (+42.13%) | -18.61M (-4.61%) | -19.51M (+17.81%) | -16.56M (+24.79%) | -13.27M (+23.44%) | -10.75M (-0.83%) | -10.84M (+42.44%) | -7.61M (+27.90%) | -5.95M |
Net Income | |||||||||||||
Income Before Tax | - | - | - | - | - | -61.90M | - | - | - | - | - | - | - |
Net Income From Continuing Operations | -23.52M (-72.97%) | -87.00M (+302.41%) | -21.62M (+11.39%) | -19.41M (-18.72%) | -23.88M (+53.18%) | -15.59M (-14.06%) | -18.14M (+14.38%) | -15.86M (+28.53%) | -12.34M (+39.59%) | -8.84M (-12.99%) | -10.16M (+33.51%) | -7.61M (+27.90%) | -5.95M |
Net Income | -23.52M (-72.97%) | -87.00M (+302.41%) | -21.62M (+11.39%) | -19.41M (-18.72%) | -23.88M (+53.18%) | -15.59M (-14.06%) | -18.14M (+14.38%) | -15.86M (+28.53%) | -12.34M (+39.59%) | -8.84M (-12.99%) | -10.16M (+33.51%) | -7.61M (+27.90%) | -5.95M |
Comprehensive Income Net Of Tax | -24.41M | - | -21.47M (+10.39%) | -19.45M (-18.55%) | -23.88M (-61.44%) | -61.93M (+243.67%) | -18.02M (+13.55%) | -15.87M (+27.98%) | -12.40M (-61.86%) | -32.51M (+220.30%) | -10.15M | - | - |